LAPTM5 c403t and HCLS1 g496a are potentially novel contributors for the genetic predisposition to familial WM.
INTRODUCTION
The evaluation of cancer occurrence within families is important for unraveling the molecular events that drive tumorigenesis. Waldenström's Macroglobulinemia (WM) represents a B-cell lymphoproliferative disorder, classified as a lymphoplasmacytic lymphoma, according to the WHO classification. 1 WM represents a rare B-cell malignancy that accounts for 1-2% of all hematologic neoplasms, with an incidence rate of 3-4 cases per million people, per year. 2, 3 Evidence also exists that IgM monoclonal gammopathy of undetermined significance (IgM MGUS) is associated with an increased risk of developing WM. 4, 5 Most recently, whole genome sequencing studies have demonstrated the occurrence of MYD88 and CXCR4/WHIM-like somatic variants in more than 90% and 30-35% of WM patients, respectively. [6] [7] [8] [9] Previous studies have identified familial aggregation of WM cases, and the clustering of B-cell lymphoproliferative disorders among first degree relatives of patients with WM, [10] [11] [12] [13] [14] [15] [16] including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (nHL), multiple myeloma (MM), IgM-MGUS and IgG/IgA-MGUS. These findings support a possible contribution of inherited susceptibility to familial WM. Nevertheless, genetic linkage studies have failed to clearly identify rare, highly-penetrant alleles underlying a subset of B-cell lymphoproliferative disorders, yielding to an oligogenic model whereby relatively common, low-penetrance alleles would contribute to the LP phenotype in familial cases. 17, 18 In fact, GWAS studies have identified common variants associated with multiple myeloma. [19] [20] [21] [22] Case control studies have similarly identified significant association with other lymphoproliferative disorders. 20, 23 Whether relatively common germline variants may contribute specifically to familial WM cases, remains unexplored.
We therefore performed whole exome sequencing on germline DNA obtained from four members of a single family with documented coinheritance of WM (three affected; 1 unaffected) and applied bioinformatic tools to identify candidate germline variants likely to have a biological role in WM signaling pathways. We screened additional 246 independent, unrelated WM cases (50 probands from familial cases and 196 individuals from non-familial cases) for the identified variants. We report that For personal use only. on March 8, 2016 . by Steven Treon www.bloodjournal.org From LAPTM5 c403t and HCLS1 g496a represent the most recurrent variants, present in 3/3 affected members of the index family. Each of these variants was present in 8% of the unrelated familial cases. Each variant was present in 0.5% of the non-familial cases and in <0.05 of a control population (1000 Genomes). These findings highlight potentially novel contributors for the genetic predisposition to familial WM, and suggest possible candidates for screening in familial WM. 
METHODS

Study oversight
Approval for these studies was obtained from the Dana-Farber Cancer Institute Institutional Review Board. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. Written consent was obtained from all study participants.
Study participants
We studied a family with three first-degree relatives that were affected with WM, and a healthy unaffected family member who was considered to be a control, and performed whole exome sequencing. A total of additional 246 participants representing individual probands affected with WM, from 246 independent families were included in these studies: 50 of the participants had a family history of WM or other B-cell lymphoproliferative disorders, while the remaining 196 were non-familial patients. Based on previous identification of familial aggregation of WM cases and clustering of B-cell lymphoproliferative disorders (including chronic lymphocytic leukemia-CLL, multiple myeloma-MM, non-Hodgkin lymphoma) among the first degree relatives of WM patients [11] [12] [13] [14] [15] [16] , we defined a familial case as a patient with first degree relatives who are also affected by a B-cell lymphoproliferative disorder, including WM, CLL, non-Hodgkin lymphoma, MM, IgM-MGUS and IgG/IgA-MGUS; non-familial cases are individuals whose family members are either healthy or are diagnosed with a solid tumor, but not a B-cell lymphoproliferative malignancy.
Sequence data generation
Genomic DNA was isolated from buccal cells collected from each study participant, including the 246 independent WM cases, and was subjected to library construction, according to standard methods, followed by shearing, end repair, phosphorylation and ligation to barcoded sequencing adapters. The DNA was sizeselected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent, Santa Clara, CA). Samples were multiplexed and sequenced on Illumina HiSeq flow cells with the 24 with default parameters, and the resulting SAM files were converted to BAM files using Picard (http://picard.sourceforge.net/). Accession number: SRP053196.
Quality control of sequencing data
To evaluate the overall quality of sequenced samples, we used BamUtil (http://genome.sph.umich.edu/wiki/BamUtil) to calculate various statistics, including the total number of reads, mapping rate, percentage of proper pairs, and duplication rate.
Given that the SureSelectQXT v4 platform covers around 51M, a mean coverage was calculated for each sample. We evaluated the distribution of the mean coverage across all targeted regions. The DepthOfCoverage function from GATK (v2.74) was used with the "-mmq 10" parameter. 27 All unmapped reads, duplicated reads and reads with low mapping quality (< 10) were removed. Finally, a more comprehensive callable analysis on all targeted bases was adopted, by considering simultaneously sequencing quality, mapping quality and coverage, according to the CallableLoci tool (GATK, Broad Institute, Cambridge, MA).
Variant Calling
Single nucleotide variants (SNVs) were called by GATK, 25 based on best practice workflow. Briefly, GATK was used for base quality score recalibration and indel realignment, followed by variant calling with use of UnifiedGenotyper with -stand_call_conf = 30.
Selection of potential WM variants
We first selected variants that occurred in affected members but were absent in the unaffected member. The resulting single nucleotide variants (SNVs) were annotated by snpEff 26 and Oncotator (http://www.broadinstitute.org/oncotator/), and variants located in exonic regions were considered for further analysis. Synonymous variants were filtered out, and the resulting SNVs were annotated with dbNSFP, a database that was developed for functional prediction and annotation of all potential non-synonymous SNVs in the human genome. 27 Allele frequencies (AF) in 1000 Genomes, as well as PolyPhen-2 prediction, were used to quantify the deleteriousness of SNVs. Variants with AF >0.05 in 1000G were filtered out, and the remaining SNVs were defined as potential familial WM-associated variants.
Differential expression analysis
Differential expression was analyzed using the bioconductor (www.bioconductor.org) package limma, in the R statistical computing environment (www.r-project.org); 28 using empirical Bayes moderated t-statistics to calculate P-values for two-class unpaired samples. Differentially expressed genes were identified using a false discovery rate (FDR) cutoff of 1%. Among the differentially expressed genes, those with more than a 2-fold change were defined as a signature.
Gene expression data
GSE12668 was used to define genes that were differentially expressed between bone marrow-derived primary WM cells and their normal counterparts. Tissue specificity for genes of interest in normal tissues was retrieved directly from Gene Enrichment Profiler (GEP) (http://xavierlab2.mgh.harvard.edu/EnrichmentProfiler/index.html).
Expression levels for genes of interest in primary cancer tissues were downloaded from the cbioportal (http://cbioportal.org), 29 which integrates data generated by the TCGA Research Network (http://cancergenome.nih.gov/) and by many other sources. Gene expression modules were assessed using an independent mRNA data set (GSE6691).
Disease gene prioritization
Given the selected potential familial WM-associated variants/genes, we used GRAIL 30 coupled with a global coexpression network COXPRESdb 31 to assess the functional relatedness between these genes and those that were differentially expressed between bone marrow-derived primary WM cells compared to their normal counterparts, using GSE12668.
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Sanger Sequencing
The observed LAPTM5, HCLS1 variants were validated by Sanger Sequencing.
The Fisher exact test was used to assess the significance of variants observed in familial cases, compared to those in non-familial cases.
3D protein modeling
Three-dimensional LAPTM5 protein reconstruction was obtained using the Phyre2 server, as described. 32
Statistics
All analyses of raw sequencing metrics were performed using the limma package in an R/bioconductor computational environment; differentially expressed genes were identified using a FDR cutoff of 1%. Fisher exact test was used to assess the significance of variants observed in familial cases compared to those in non-familial cases. 
RESULTS
Identification of LAPTM5 c403t and HCLS1 g496a variants in familial WM
We studied a kindred in which three members are affected by familial WM (Fig.   1A ). The diagnosis of WM was confirmed in all cases by histology and immunohistochemistry, 33 and clinical features are summarized within Suppl. Table 1 .
Whole exome sequencing was performed on the three affected members and one of unaffected members. The criteria to identify candidate WM-associated variants were nonsynonymous SNVs that were present only in the affected family members and absent in the unaffected member and an allele frequency <0.05 using the 1000 Genomes. This initial screen identified 132 candidate exonic, non-synonymous familial WM variants, mapping to 127 genes ( Fig. 1B ; Suppl. Table 2 ; Suppl. Fig. 1 ). We next performed a gene/variant prioritization in order to select the most significant WM relevant variants, by using Gene Relationships Across Implicated Loci (GRAIL), 30 which integrates text mining or co-expression databases for gene prioritization. GRAIL takes a group of seed genes to build a sub-network and test whether a query gene is functionally related to the seeds. Since the seeds should be disease related genes, we used a WM gene expression signature as seeds; and then queried the potential WM variants identified in this study for prioritization. The publically available gene expression data set (GSE12668) 34 was evaluated to define a WM cell-mRNA signature by comparing primary bone marrowderived CD19+ WM tumor cells obtained from newly diagnosed untreated WM patients with their normal counterparts obtained from healthy individuals (HD); we found 393 genes that were significantly different between WM patients and healthy individuals, thus confirming the presence of a specific WM mRNA signature (false discovery rate -FDRcutoff <1%), ( Fig. 2A ; Suppl. Table 3 ). We next assessed the functional relatedness between potential familial WM-associated genes and the observed WM mRNA signature, using the GRAIL algorithm 30 coupled with a global co-expression network COXPRESdb, as reported. 31 Using an FDR cutoff of 5%, 13 genes were predicted to be functionally related to the WM mRNA signature (Fig. 2B ). In addition, the observed germline variants were annotated and interpreted by implementing Polymorphism Phenotyping v2 (PolyPhen-2), as described, 35 thus allowing a prioritization for the deleteriousness of single nucleotide variants (SNVs) shared between all three affected WM family members.
It has been reported that disease-related genes tend to be tissue specific; 36 we therefore assessed the tissue specificity of the selected genes for further prioritization.
The Gene Enrichment Profiler (GEP) database contains expression profiles and tissue specificity scores for ~12,000 genes across 126 normal primary human tissues and 23 cancers. 37 WM is a B-cell lymphoproliferative disorder, and is classified as an IgMsecreting lymphoplasmacytic lymphoma: 1 we thus utilized the GEP database to assign a score to each of the selected genes, which was the average of its tissue specificity score across normal B cells. We reasoned that genes containing deleterious variants that are significantly related to the WM mRNA expression signature, and are also highly specific to B-cells, may be the most promising familial WM-associated genes. Among the 13 potential candidate genes obtained as the result of the network-based gene prioritization algorithm, independently of any B-cell tissue specificity filtering criteria, the most significant gene candidates were found to be hematopoietic cell-specific Lyn substrate 1 (HCLS1) and lysosomal protein transmembrane 5 (LAPTM5) (Fig. 2C ; Suppl. Table 4 ).
Variants in these two genes co-segregated within the affected family members; being absent in the un-affected family member; and present in less than 1% of the control population, where allele frequency and heterozigote frequency were 0.38%/0.7% and 0.39%/0.7% for LAPTM5 and HCLS1, respectively, using the 1000 Genomes (Suppl. Table 5 ). Both genes are highly B-cell tissue specific (Suppl. Fig. 2A -B-C). In contrast, the two control genes HRC and IL22RA1 (which are not functionally related to WM expression signature, but contain benign variants) are not B-cell specific (Suppl. Fig. 3A-B ). The Cancer Genome Atlas (TCGA) revealed that the expression of LAPTM5 and HCLS1 is specifically enriched in patients with lymphoid malignancies (diffuse large Bcell lymphoma), as compared to solid tumors (Fig. 2D) . These findings were further corroborated by analyzing 1037 tumor cell lines deposited in the Cancer Cell Line Encyclopedia (CCLE), which showed a significant enrichment of both LAPTM5 and HCLS1 in hematopoietic-related tumors (Suppl. Fig. 4A-B ). Taken together, these observations suggest that LAPTM5 and HCLS1 are both relevant candidate genes for characterizing familial WM individuals, and are also relevant to the tumor clone. Table 6 ; P 0.007). Notably, the 4 familial members that presented with the LAPTM5 c403t germline aberration, had a family history of either WM (n:2), MM (n:1), or nHL (n:1) (Fig. 3A) . The variant is located in exon 5 of the LAPTM5 gene ( Fig. 3B ). LAPTM5 is a 29-kDA protein, consists of 5 hydrophobic trans-membrane helical domains, and is preferentially expressed in cells of lymphoid and myeloid origin 38 . The variant is predicted as missense mutation that causes an amino-acid substitution from proline to serine at the 4 th trans-membrane helical domain (LAPTM5 P135S ; Fig. 3C ).
Sanger sequencing also confirmed the HCLS1 g496a variant to be detectable in the original family, being present in 3/3 patients with familial WM and absent in the unaffected family member. The presence of the HCLS1 g496a variant was confirmed in four out of 50 (8%) of independent familial WM cases (4/50), and in 1 out of 196 (0.5%) of the non-familial cases, documenting a statistically significant difference in the numbers of patients carrying the HCLS1 g496a variant in familial versus non-familial cases (Suppl. Table 6 ; P 0.007). Notably, the 4 patients with familial WM that presented with the HCLS1 g496a germline aberration, had a family history of CLL (n: 2), WM (n: 1) or nHL (n: 1) (Fig. 4A) . The variant is located within exon 7 of the HCLS1 gene (Fig. 4B ).
For personal use only. on March 8, 2016 . by Steven Treon www.bloodjournal.org From HCLS1 is a 79-KDa intracellular protein that consists of an Arp2/3 complex binding domain, 3.5 tandem repeats, and a coiled-coil region that binds to F-actin and a Cterminal SH3 domain. 39 The variant is predicted as a missense mutation that causes an amino-acid substitution from aspartic acid to asparagine at the 3 rd HS1 repeat (HCLS1 D166N ; Fig. 4C ).
LAPTM5 and HCLS1 impact on WM disease biology
To interrogate a possible involvement of LAPTM5 and HCLS1 in WM biology, we used the HEFalMp database to construct two modules for LAPTM5 and HCLS1. The HEFalMp database provides a global gene-gene association map, predicted by integrating hundreds of publicly available genomic datasets, 40 and led to identification of the top 25 genes associated with LAPTM5 or HCLS1 (Fig. 5A ). Of note, HCLS1 was part of the LAPTM5 module, and vice versa, suggesting that both genes function through the same biological module. In addition, 52% of the identified genes were shared between the two modules.
Besides LAPTM5 and HCLS1, the two other known WM-related genes MYD88
and TNFAIP3, were also present in this sub-network: the MYD88 L265P somatic mutation is present in 91% of patients with WM, 6 and TNFAIP3, occurring in the context of the 6q deletion, is the most frequent cytogenetic event described in WM. 41 Of note, while MYD88 belonged to the HCLS1 module, TNFAIP3 appeared within the LAPTM5 module.
We next interrogated the most significant pathways that were connected to each sub-network by using a gene-pathway connectivity map, generated by integrating 70K microarray, FANTOM 5 and protein-protein interaction data, as previously reported. 42 Statistically significant pathways were identified testing 184 KEGG pathways and using permutation test, with adjusted p-value of 0.05. The LAPTM5 and HCLS1 sub-networks shared similar enriched pathways, including immune-related pathways, B-cell receptor-, JAK/STAT-, VEGF-and chemokine-signaling pathways, as well as cytokine-cytokine receptor interaction (Suppl. Table 7 ).
We combined the LAPTM5 and HCLS1 modules into a single WM-associated module, and investigated whether this module is disrupted in WM patients compared to HDs, 43 using an independent gene expression profile dataset (GSE6691), 44 and demonstrated a statistically significant high gene-to-gene connectivity in HDs ( Fig. 5B -C); in contrast, gene-to-gene connectivity was significantly inferior in WM cells (Fig.   5D ), wherein the sub-network was disrupted (Fig. 5E ). Using 10,000 random modules with the same size as background, we found that the change in mean connectivity was significantly different in the WM-versus the HD-modules (P<0.0001, Fig. 5F ). Together, these findings suggest a conserved high interactivity between LAPTM5 and HCLS1 in normal B cells, while WM cells present a disrupted pattern of connectivity, which likely impacts disease biology.
DISCUSSION
Recent studies on the genomic landscape of WM have described recurrent somatic aberrations, including MYD88 L265P and CXCR4 S338X , [6] [7] [8] 45 while the germline determinants of familial WM cases remain unexplored. We have shown that the LAPTM5 c403t variant may predispose to familial WM and that in transformed WM cells there is a disrupted pattern of connectivity, between LAPTM5 and MYD88, leading to the hypothesis that these two genes may interplay in supporting the pathogenesis of this disease.
In summary, the identification of a germline variant in genes that display oncogenic properties in B-cell lymphoproliferative disorders offers new insights into the molecular mechanisms of lymphoplasmacytic lymphoma pathogenesis, particularly in WM. The LAPTM5 and HCLS1 genes show relevant tissue-specific expression for WM and predicted functional relationship to WM phenotype by expression signature. The specific and recurrent LAPTM5 c403t and HCLS1 g496a variants observed in this study demonstrated segregation with disease in a striking familial WM pedigree and enrichment in other familial cases.
According to allele and genotype frequencies from the 1000 Genomes database, about 1 out of 132 people (0.7%) in the general population carries either the HCLS1 g496a or the LAPTM5 c403t variant. It is therefore expected that roughly 1 in 17,000 (0.0058%) individuals in the general population carries both of these independently assorting variants. This latter number aligns with population estimates of WM prevalence. WM represents a rare phenotype that could plausibly require more predisposing genetic factors on average than associated and much more common B-cell lymphoproliferative disorders.
This would be consistent with our finding of both the LAPTM5 c403t and the HCLS1 g496a variants in the three individuals affected with WM in our primary study family for this report. Familial cases with less striking family history were enriched for one variant or the other, but none had both. One can envision a model by which two risk variants predispose to WM by a combinatorial mechanism. A polygenic mode also remains possible.
Previous studies have reported on LAPTM5 over-expression in patients with Bcell lymphomas. 46 Our findings indicate LAPTM5 c403t as the most significantly predicted variant to be functionally related to the WM mRNA signature. Of note, LAPTM5 has been shown to support NF-κB activation upon TNF-α stimulation, 47 and primary WM cells reportedly present with a constitutive activation of the NF-κB pathway: 48 we may therefore hypothesize that mutated LAPTM5 may possibly contribute to NF-kB modulation in WM cells. Further studies would be needed to better characterize the relevance of LAPTM5 c403t in regulating canonical and non-canonical NF-kB activity in WM cells at protein level, and the potential relevance of the variant in regulating WM cell proliferation.
LAPTM5 c403t and HCLS1 g496a may represent predisposition alleles in patients with familial WM. Future studies will be needed to clarify the penetrance of specific alleles as well as possible combinatorial effects. Our findings suggest that the contribution of the LAPTM5 c403t and HCLS1 g496a variants to WM susceptibility should be further investigated. 
